Showing 31-40 of 149 results for "".
Dermwire TV: Topical Caffeine for Hair Growth, Tapinarof for Pediatric AD
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-topical-caffeine-for-hair-growth-tapinarof-for-pediatric-ad/48734/This episode highlights studies showing potential for topical caffeine in hair growth in patients with alopecia areata, as well as recent positive results for tapinarof cream 1% for children with AD. Also, Cutera CEO Taylor Harris talks with Practical Dermatology about the evolving needs of today’sNIH Analysis Examines Association Between AD and Comorbidities
https://practicaldermatology.com/programs/practical-dermatology-atopic-dermatitis/nih-analysis-examines-association-between-ad-and-comorbidities/27113/In this week's DermwireTV, new NIH data looks at the association between AD and several health conditions; a study evaluates the effect of lebrikizumab monotherapy in patients with moderate-to-severe AD over 16 weeks; and Andrew Mastro provides tips on how to optimize the first 5 minutes with a patiStarting a Systemic Therapy in Atopic Dermatitis or Psoriasis
https://practicaldermatology.com/series/pa-perspectives/Starting-a-Systemic-Therapy-in-Atopic-Dermatitis-or-Psoriasis/26644/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses how to talk to patients about starting a systemic therapy in atopic dermatitis or psoriasis; how to keep the conversation to 7 minutes; and the importance ofI decided to become a dermatologist when...
https://practicaldermatology.com/topics/practice-management/i-decided-to-become-a-dermatologist-when-/18683/PD Asks Andrew Menkes, MD when he decided to be a dermatologist. Hear how he settled on a speciality that "in those days...wasn't so glamorous." In fact, Dr. Menkes says he didn't even tell some peers about his residency. Watch other responses to this question: Yolanda Lenzy, MD, MPHDermWireTV: Diagnosing Melanoma Using Deep-Learning Model; New Adbry Approval
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-diagnosing-melanoma-using-deep-learning-model-new-adbry-approval/26445/In this week's DermWireTV, researchers develop a novel deep-learning model designed to more accurately diagnose melanoma; LEO Pharma receives a new approval for atopic dermatitis drug Adbry; and in our PA Perspectives segment, Andrew Mastro discusses how to build an inflammatory clinic.FDA Approves Rosacea Treatment Emrosi
https://practicaldermatology.com/series/dermwire-tv/fda-approves-rosacea-treatment-emrosi/29207/In this week's DermwireTV, the FDA approves a first-of-its-kind treatment for rosacea in adults; two companies with approved atopic dermatitis products provide new long-term efficacy and safety data; and Andrew Mastro discusses how to recognize physician burnout.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.New Analysis of Benzene Contamination in BPO Products
https://practicaldermatology.com/series/dermwire-tv/new-analysis-benzene-contamination-bpo-products/29074/In this week's DermwireTV, new data continues to raise concerns about benzene contamination in BPO products; the FDA expands the approved dosage for Ameluz for actinic keratosis (AK); and in our PA Perspectives segment, Andrew Mastro discusses how to approach a contract negotiation.FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuPA Perspectives - Building a Schedule
https://practicaldermatology.com/series/pa-perspectives/pa-perspectives-building-schedule/24488/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, provides insights on what a PA should be providing to an MD and their office staff. He also discusses realistic expectations for a new PA regarding scheduling, and giv